Bain Capital Life Sciences Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 16
- Investments
- 64
- Portfolio
- 29
- Exits
- 30
Bain Capital Life Sciences General Information
Description
Founded in 2016, Bain Capital Life Sciences is a corporate venture capital arm of Bain Capital and is based in Boston, Massachusetts. The firm seeks to invest in seed-stage, early-stage, and later-stage companies. The firm seeks to invest in the companies operating in the healthcare devices and supplies, biopharmaceutical, specialty pharmaceutical, diagnostics, and enabling life science technology sectors.
Contact Information
Website
www.baincapitallifesciences.com
Year Founded
2016
Investor Status
Actively Seeking New Investments
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Growth/Expansion
PE/Buyout
Real Estate
Primary Office
- 200 Clarendon Street
- Boston, MA 02116
- United States
+1 (617) 000-0000
Bain Capital Life Sciences Investments (64)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Affera | 20-Dec-2021 | Later Stage VC | 0000 | Therapeutic Devices | Generating Revenue | 0000000 00000000 |
| 0000 | 17-Dec-2021 | 0000 | 00.00 | Drug Discovery | Generating Revenue | |
| 00000000 | 07-Dec-2021 | 00000 00000 | 00000 | Laboratory Services (Healthcare) | Clinical Trials - General | |
| 000000000 000000 | 27-Oct-2021 | 00000 00000 | 00000 | Biotechnology | Pre-Clinical Trials | 0000 000000 00.0 |
| 0000000 0000000000 | 29-Sep-2021 | 0000 | 00000 | Biotechnology | Generating Revenue | |
| 00000 000000000000 | 10-Aug-2021 | 0000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
| 000000 | 20-Jul-2021 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 3 | |
| 0000000000 0000 | 15-Jul-2021 | 00000 00000 | 00000 | Therapeutic Devices | Generating Revenue | 000000 0000 00.0 |
| Synthekine | 10-Jun-2021 | Early Stage VC | 00000 | Drug Discovery | Pre-Clinical Trials | |
| Nautilus Biotechnology | 09-Jun-2021 | PIPE | 00000 | Biotechnology | Generating Revenue/Not Profitable |
Bain Capital Life Sciences Exits (30)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Amunix Pharmaceuticals | 08-Feb-2022 | Merger/Acquisition | 00.000 |
| 000000 | 07-Jan-2022 | 000 | 00000 |
| 00000 000000000000 | 22-Oct-2021 | 000 | 00000 |
| 000000 00000000000 | 06-Aug-2021 | 000 | 00000 |
| 00000000 | 29-Jul-2021 | 000 | 00000 |
| 00000 00000 000000 | 15-Jul-2021 | 000 | 00000 |
| 0000000 0000000000 | 02-Jul-2021 | 000000 0000000000 | 00000 |
| 000000000 | 05-Feb-2021 | 000 | 00000 |
| Thrive Earlier Detection | 05-Jan-2021 | Merger/Acquisition | 00.000 |
| Atea Pharmaceuticals | 30-Oct-2020 | IPO | 00000 |
Bain Capital Life Sciences Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialBain Capital Life Sciences Team (18)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Adam Koppel Ph.D | Managing Director | 0 | 0 | 0 | Boston, MA |
| Jeffrey Schwartz | Managing Director | 0 | 0 | 0 | Boston, MA |
| Amir Zamani MD | Principal | 0 | Boston, MA | ||
| Nicholas Downing MD | Principal | 0 | Boston, MA | ||
| Melissa Danforth JD | Transactions Counsel, North America Private Investments | Boston, MA |
Bain Capital Life Sciences Co-Investors (177)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| RA Capital Management | 10 | 0 | 0 |
|
|
| Rock Springs Capital | 0 | 0 | 0 |
|
|
| Perceptive Advisors | 0 | 0 | 0 |
|
|
| Janus Henderson Investors | 0 | 0 | 0 |
|
|
| Logos Capital | 0 | 0 | 0 |
|
|